These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22893483)

  • 21. Multi-stage dose expansion cohort (MSDEC) design with Bayesian stopping rule.
    Wang S; Tan M
    J Biopharm Stat; 2022 Jul; 32(4):600-612. PubMed ID: 35699319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The continual reassessment method for multiple toxicity grades: a bayesian model selection approach.
    Pan H; Zhu C; Zhang F; Yuan Y; Zhang S; Zhang W; Li C; Wang L; Xia J
    PLoS One; 2014; 9(5):e98147. PubMed ID: 24875783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective robustness of the continual reassessment method.
    O'Quigley J; Zohar S
    J Biopharm Stat; 2010 Sep; 20(5):1013-25. PubMed ID: 20721788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-finding design for multi-drug combinations.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2011 Aug; 8(4):380-9. PubMed ID: 21652689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples.
    van Werkhoven E; Hinsley S; Frangou E; Holmes J; de Haan R; Hawkins M; Brown S; Love SB
    BMC Med Res Methodol; 2020 Jun; 20(1):162. PubMed ID: 32571298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continual reassessment method for ordered groups.
    O'Quigley J; Paoletti X
    Biometrics; 2003 Jun; 59(2):430-40. PubMed ID: 12926728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adaptive prior variance calibration in the Bayesian continual reassessment method.
    Zhang J; Braun TM; Taylor JM
    Stat Med; 2013 Jun; 32(13):2221-34. PubMed ID: 22987660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West.
    Morita S
    Stat Med; 2011 Jul; 30(17):2090-7. PubMed ID: 21500239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A nonparametric Bayesian method for dose finding in drug combinations cancer trials.
    Razaee ZS; Cook-Wiens G; Tighiouart M
    Stat Med; 2022 Mar; 41(6):1059-1080. PubMed ID: 35075652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A hybrid Bayesian adaptive design for dose response trials.
    Chang M; Chow SC
    J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accuracy, Safety, and Reliability of Novel Phase I Trial Designs.
    Zhou H; Yuan Y; Nie L
    Clin Cancer Res; 2018 Sep; 24(18):4357-4364. PubMed ID: 29661774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
    Resche-Rigon M; Zohar S; Chevret S
    Clin Trials; 2008; 5(6):595-606. PubMed ID: 19029208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies.
    Zohar S; Chevret S
    Stat Med; 2001 Oct; 20(19):2827-43. PubMed ID: 11568943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials.
    Ishizuka N; Ohashi Y
    Stat Med; 2001 Sep 15-30; 20(17-18):2661-81. PubMed ID: 11523075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incorporating lower grade toxicity information into dose finding designs.
    Iasonos A; Zohar S; O'Quigley J
    Clin Trials; 2011 Aug; 8(4):370-9. PubMed ID: 21835856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.
    Bayar MA; Ivanova A; Le Teuff G
    Comput Methods Programs Biomed; 2019 Jul; 176():211-223. PubMed ID: 31200907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.
    Zhao D; Zhu J; Wang L
    Contemp Clin Trials; 2021 Mar; 102():106265. PubMed ID: 33418097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continual reassessment method: a likelihood approach.
    O'Quigley J; Shen LZ
    Biometrics; 1996 Jun; 52(2):673-84. PubMed ID: 8672707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-escalation designs in oncology: ADEPT and the CRM.
    Shu J; O'Quigley J
    Stat Med; 2008 Nov; 27(26):5345-53; discussion 5354-5. PubMed ID: 18752259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A nonparametric Bayesian continual reassessment method in single-agent dose-finding studies.
    Tang N; Wang S; Ye G
    BMC Med Res Methodol; 2018 Dec; 18(1):172. PubMed ID: 30563454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.